MEDIFAST INC Form 10-Q November 09, 2010

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2010

OR

" TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

Commission file number 0-23016

MEDIFAST, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of organization)

13-3714405 (I.R.S. employer Identification no.)

11445 Cronhill Drive Owings Mills, MD 21117 Telephone Number (410) 581-8042

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No "

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer "

Accelerated filer x

Non-accelerated filer "

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes " No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class
Common stock, \$.001 par value per share

Outstanding at November 8, 2010 15,421,601 shares

Medifast, Inc. Index

Part I - Financial Information:	
Item 1 – Financial Statements	3
Condensed Consolidated Balance Sheets as of September 30, 2010 (unaudited) and December 31, 2009 (audited)	3
Condensed Consolidated Statements of Income (unaudited) for the Three and Nine months Ended September 30, 2010 and 2009	4
Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the Nine months Ended September 30,2010	5
Condensed Consolidated Statements of Cash Flows (unaudited) for the Nine months Ended September 30, 2010 and 2009	6
Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2 - Management's Discussion and Analysis of Financial Condition And Results of Operations	15
Item 3 – Quantitative and Qualitative Disclosures about Market Risk	25
Item 4 – Controls and Procedures	25
Part II - Other Information:	
Item 1 – Legal Proceedings	26
Item 1A – Risk Factors	26
Item 5 – Other Information	26
Item 6 - Exhibits	28
2	

Part I. Financial Information Item1. Financial Statements

MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited) (Audited) September 30, 2010 December 31, 2009

ASSETS				
Current assets				
Cash and cash equivalents	\$	20,211,000	\$	10,604,000
Accounts receivable-net of allowance for sales returns and doubtful	Ψ	20,211,000	Ψ	10,001,000
accounts				
of \$288,000 and \$100,000 respectively		864,000		676,000
Inventory		17,540,000		11,232,000
Investment securities		16,431,000		5,699,000
Deferred compensation		-		641,000
Income taxes - prepaid		3,055,000		2,211,000
Prepaid expenses and other current assets		1,402,000		3,123,000
Note receivable - current		46,000		46,000
Deferred tax asset		156,000		100,000
Total current assets		59,705,000		34,332,000
Property, plant and equipment - net		28,046,000		23,237,000
Trademarks and intangibles - net		3,237,000		4,104,000
Note receivable, net of current assets		109,000		112,000
Other assets		223,000		379,000
TOTAL ASSETS	\$	91,320,000	\$	62,164,000
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities				
Accounts payable and accrued expenses		14,548,000		4,967,000
Income taxes payable		-		22,000
Current maturities of long-term debt		953,000		796,000
Total current liabilities		15,501,000		5,785,000
Other liabilities				
Long-term debt, net of current portion		5,083,000		5,444,000
Deferred tax liability		1,755,000		1,360,000
Total liabilities		22,339,000		12,589,000
Stockholders' Equity:				
Preferred stock, \$.001 par value (1,500,000 authorized, no shares issued and				
outstanding)		-		-
Common stock; par value \$.001 per share; 20,000,000 shares authorized;				
15,421,601 issued and 15,052,693 outstanding at 9/30/10 and 15,398,941				
issued and 15,031,103 shares outstanding at 12/31/09		16,000		16,000

Additional paid-in capital	31,670,000	28,456,000
Accumulated other comprehensive income (loss)	197,000	159,000
Retained earnings	40,453,000	24,264,000
Less: cost of 368,908 and 367,838 shares of common stock in treasury	(3,355,000)	(3,320,000)
Total stockholders' equity	68,981,000	49,575,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY